| COVID-19 Clinical Research Studies | Lifetime | 72 | QA 1 | 99.48 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 89 | QA 1 | 99.54 |
| SARS-CoV-2 detection and testing | Lifetime | 38 | QA 1 | 98.91 |
| Herpesvirus Infections and Treatments | Lifetime | 248 | QA 1 | 98.46 |
| Hepatitis B Virus Studies | Lifetime | 403 | QA 1 | 98.88 |
| Hepatitis C virus research | Lifetime | 385 | QA 1 | 98.89 |
| HIV, Drug Use, Sexual Risk | Lifetime | 179 | QA 1 | 98.76 |
| COVID-19 epidemiological studies | Lifetime | 229 | QA 1 | 98.19 |
| Adolescent Sexual and Reproductive Health | Lifetime | 297 | QA 1 | 98.41 |
| HIV/AIDS Research and Interventions | Lifetime | 577 | QA 1 | 98.63 |
| Reproductive tract infections research | Lifetime | 260 | QA 1 | 97.79 |
| Vaccine Coverage and Hesitancy | Lifetime | 373 | QA 1 | 97.42 |
| Genital Health and Disease | Lifetime | 708 | QA 1 | 94.63 |
| Sex work and related issues | Lifetime | 901 | QA 1 | 91.74 |
| Bartonella species infections research | Lifetime | 203 | QA 1 | 89.01 |
| Poxvirus research and outbreaks | Lifetime | 807 | QA 1 | 87.70 |
| Female Genital Mutilation/Cutting Issues | Lifetime | 359 | QA 1 | 83.43 |
| HIV, TB, and STIs Epidemiology | Lifetime | 156 | QA 1 | 80.65 |
| Immune responses and vaccinations | Lifetime | 967 | QA 1 | 79.95 |
| COVID-19 Clinical Research Studies | 2021-2025 | 14 | QA 1 | 99.85 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 12 | QA 1 | 99.86 |
| SARS-CoV-2 detection and testing | 2021-2025 | 9 | QA 1 | 99.40 |
| Herpesvirus Infections and Treatments | 2021-2025 | 6 | QA 1 | 98.81 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 40 | QA 1 | 98.92 |
| COVID-19 epidemiological studies | 2021-2025 | 136 | QA 3 | 97.74 |
| Viral gastroenteritis research and epidemiology | 2021-2025 | 263 | QA 2 | 94.74 |
| Reproductive tract infections research | 2021-2025 | 147 | QA 1 | 93.15 |
| Cytomegalovirus and herpesvirus research | 2021-2025 | 231 | QA 1 | 90.21 |
| Bartonella species infections research | 2021-2025 | 19 | QA 1 | 87.99 |
| Hepatitis B Virus Studies | 2021-2025 | 940 | QA 2 | 87.49 |
| Parvovirus B19 Infection Studies | 2021-2025 | 156 | QA 1 | 84.10 |
| Adolescent Sexual and Reproductive Health | 2021-2025 | 763 | QA 1 | 86.39 |
| Genital Health and Disease | 2021-2025 | 505 | QA 4 | 80.30 |
| Syphilis Diagnosis and Treatment | 2021-2025 | 593 | QA 1 | 68.71 |
| Immune responses and vaccinations | 2021-2025 | 756 | QA 2 | 60.66 |
